The 12 most recent market catalysts affecting $SYK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 55
TD Cowen Maintains Hold on Stryker, Lowers Price Target to $298
TD Cowen analyst Mathew Blackman maintained a 'Hold' rating on Stryker (SYK) but lowered the price target from $355 to $298. This action indicates a revised valuation perspective f…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on Stryker, Lowers Price Target to $348
Wells Fargo analyst Larry Biegelsen maintained an 'Overweight' rating on Stryker (SYK), indicating a positive long-term outlook for the company. However, the price target was signi…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
Stryker Announces Deal To Acquire Rotator Cuff Augmentation Firm ZuriMED; Terms Not Disclosed
This acquisition by Stryker (SYK) is a strategic move to enhance its sports medicine offerings, specifically in rotator cuff repair. While the financial terms are undisclosed, the …
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 60
Citizens Maintains Market Outperform on Stryker, Lowers Price Target to $400
Citizens analyst David Turkaly has adjusted Stryker's (SYK) price target down to $400 from $440, while reaffirming a 'Market Outperform' rating. This move suggests that while the a…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Stryker, Lowers Price Target to $420
RBC Capital analyst Kendall Au maintained an 'Outperform' rating on Stryker (SYK) but lowered the price target from $435 to $420. This action signals that while the analyst still v…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 65
JP Morgan Maintains Overweight on Stryker, Lowers Price Target to $350
JP Morgan's decision to lower Stryker's price target from $400 to $350, while maintaining an 'Overweight' rating, suggests a recalibration of valuation expectations rather than a f…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 55
Piper Sandler Maintains Overweight on Stryker, Lowers Price Target to $390
Piper Sandler analyst Matt O'Brien maintained an 'Overweight' rating on Stryker but lowered the price target from $420 to $390. This action signals that while the analyst still bel…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 75
Stryker shares are trading lower after the company reported Q2 financial results. BTIG lowered its price target on the stock from $371 to $358.
The headline signals a negative corporate catalyst for Stryker, driven by Q2 financial results that likely fell short of analyst expectations or guidance. The subsequent price targ…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 95
Stryker Q2 Adj. EPS $5.75 Beats $3.49 Estimate, Sales $6.589B Beat $6.579B Estimate
Stryker (SYK) announced Q2 adjusted EPS of $5.75, significantly surpassing the analyst consensus of $3.49, an 83.71% increase year-over-year. Sales also beat estimates, coming in a…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
Correction: Stryker Q2 Adj. EPS $3.69 Beats $3.49 Estimate, Sales $6.589B Beat $6.579B Estimate
Stryker announced its second-quarter earnings, revealing adjusted EPS of $3.69, which significantly beat the analyst consensus of $3.49 by 5.73%. Sales also surpassed expectations,…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 85
Shares of medical device-related companies are trading lower after HCA Healthcare noted a Q2 increase in uninsured patient volumes and a decline in surgical volume, which may dim the outlook for device pricing power and margins.
HCA Healthcare's report acts as a bellwether for the broader healthcare services sector, particularly for companies reliant on elective procedures. The increase in uninsured patien…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.